Grants8 logo Grants8
Login Create account

Grants8

Search for grants with us!

Keywords

You can filter by below criteria

Grants

Grants you might be eligible for

Grant Information Key Details Eligibility & Funding

NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies with Humans Required)

PA-24-195

Programme: NIH Pathway to Independence Award (K99/R00)

This grant, the NIH Pathway to Independence Award (K99/R00), aims to help outstanding postdoctoral researchers successfully transition from mentored positions to independent, tenure-track or equivalent faculty roles. Its core objective is to provide independent NIH research support to facilitate the launch of competitive, self-sufficient research careers for these individuals. The grant specifically targets postdoctoral researchers with a research and/or clinical doctorate degree who are ready to undertake basic science experimental studies involving human participants, aligning with NIH's definition of both a clinical trial and basic research. This is a SECTOR-SPECIFIC grant, focusing exclusively on biomedical, behavioral, and clinical research, particularly studies involving basic experimental research with humans. The geographic scope is limited to the United States; foreign organizations cannot apply, though foreign components of projects within U.S. institutions are allowed. Key filtering criteria include the applicant's career stage (postdoctoral, no more than 4 years of experience), their doctoral degree, and the nature of their proposed research (basic experimental studies with humans). This is a recurring funding opportunity with multiple application deadlines each year until its expiration.

Funding

Up to 249000.00 USD

Deadline

Feb. 12, 2027, 10 p.m.

Details

Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)

RFA-MD-24-006

Programme: Small Business Innovation Research (SBIR) Grant

The core objective of this grant is to invite eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications. The aim is to develop innovative products, processes, or services for commercialization that will improve minority health and/or reduce and ultimately eliminate health disparities in one or more populations that experience health disparities within the United States and its territories. The grant is SECTOR-SPECIFIC, primarily targeting healthcare and health technology innovations. It seeks solutions that are effective, affordable, and culturally acceptable for racial/ethnic minority populations, disadvantaged socioeconomic groups, and underserved rural populations in the U.S. This is a recurring grant program, reissued annually, with multiple application cycles.

Funding

Up to 2045816.00 USD

Deadline

Dec. 9, 2026, 5 p.m.

Details

Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)

PAR-25-183

Programme: Exploratory/Developmental Grants Phase II (R33)

The core objective of this grant is to support the early-stage testing of pharmacologic or neuromodulatory device-based interventions for mental disorders. This involves using an 'experimental medicine approach' to rigorously validate molecular or circuit-based targets and evaluate their association with neurophysiological, behavioral, or clinical benefits. The grant is designed for research institutions, non-profits, for-profit organizations (including small businesses), and government entities capable of conducting complex clinical trials. It is a SECTOR-SPECIFIC grant, targeting the healthcare, mental health, pharmaceutical, and neuromodulation sectors. Geographically, it is open to organizations located in the United States and non-U.S. entities (foreign organizations). Key filtering criteria for initial screening: - Project must be an NIH-defined 'clinical trial'. - Focus on 'early-stage' intervention testing. - Must include 'objective measurement of molecular/circuit-based target engagement'. - Requires 'strong preliminary data' demonstrating target modulation. - Grant is a recurring opportunity with multiple submission deadlines, part of the R33 Exploratory/Developmental Phase II program.

Funding

Up to None USD

Deadline

Oct. 15, 2027, 5 p.m.

Details

Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)

PAR-25-210

Programme: National Institutes of Health (NIH)

The core objective of this grant is to support highly innovative mechanistic research focused on developing effective precision probiotic interventions. It aims to identify, understand, and address human heterogeneity that leads to inconsistent responses to probiotic treatments.
  • Target recipients: Research-performing organizations, including higher education institutions, nonprofits, for-profit businesses (small and large), and various government entities.
  • SECTOR-SPECIFIC: This grant is highly sector-specific, focusing on health, microbiome research, and the development of precision probiotic therapies.
  • Geographic scope: Organizations based in the United States are eligible to apply. Foreign components (collaborators) are allowed as part of a US-led project, but foreign organizations cannot be lead applicants.
  • Key filtering criteria: Focus on mechanistic research on probiotics, requiring preliminary data on host biological patterns, and excluding efficacy or effectiveness clinical trials.
  • Grant frequency: This is a recurring funding opportunity, noted as a 'Reissue' of a previous PAR.

Funding

Up to 350000.00 USD

Deadline

June 2, 2027, 5 p.m.

Details

Open topic on modern information and forensic evidence analysis and on frontline policing

HORIZON-CL3-2025-01-FCT-01

Programme: Horizon Europe

This grant is an open topic within the Civil Security for Society program, designed to support projects that address new, upcoming, or unforeseen challenges and/or develop creative or disruptive solutions for improving modern information and forensic evidence analysis or frontline policing. It aims to enhance the capabilities of security practitioners in preventing, detecting, and investigating criminal and terrorist offenses. This is a sector-specific grant, primarily targeting entities within the law enforcement and civil security domains. The target recipients are mainly public authorities and potentially other organizations, with a mandatory requirement for Police Authorities to be actively involved. Geographically, the grant is open to organizations from EU Member States and Associated Countries. Key filtering criteria for initial screening are the mandatory involvement of at least two Police Authorities from different eligible countries and the focus on research and innovation within the specified areas. The grant is part of the Horizon Europe Work Programme 2025, indicating it is likely a recurring program.

Funding

Up to 3000000.00 EUR

Deadline

Nov. 12, 2025, midnight

Details

Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data

PAR-25-109

Programme: Gabriella Miller Kids First Pediatric Research Program

GRANT PURPOSE AND TARGET: - The core objective of this grant is to support small research projects that analyze genomic and phenotypic data from the Gabriella Miller Kids First Pediatric Research Program (Kids First) related to childhood cancers and structural birth defects. - It also supports the development of new approaches, tools, or algorithms for analyzing this Kids First data. - Target recipients are diverse organizations with research capacity, including universities, non-profits, for-profits, and various government entities. - This grant is SECTOR-SPECIFIC, focusing on pediatric health research, genomics, and data science applied to childhood cancer and structural birth defects. - Geographic scope is international, as Non-domestic (non-U.S.) Entities are eligible. - Key filtering criteria: Applicant must have access to or propose to use Kids First X01 datasets; project must not involve clinical trials; focus on data analysis or tool development related to pediatric cancer/birth defects genomics. - This is a recurring funding opportunity, a reissue of a previous announcement (PAR-23-075), indicating an ongoing program context.

Funding

Up to 200000.00 USD

Deadline

Oct. 16, 2025, 10 p.m.

Details

Commercial Fishing Occupational Safety Training Project Grants (T03)

RFA-OH-22-006

Programme: Occupational Safety and Health Training Project Grants

This grant aims to significantly improve the quality and availability of occupational safety training for United States commercial fishermen. It supports projects focused on developing and implementing training programs, increasing the number of qualified marine safety instructors, and evaluating the effectiveness of these training initiatives in reducing injuries. This is a SECTOR-SPECIFIC grant, exclusively targeting the commercial fishing industry. It's a recurring funding opportunity, part of a program established by the Coast Guard Authorization Act.

Funding

Up to 975000.00 USD

Deadline

Jan. 26, 2027, 10 p.m.

Details

Real time monitoring of regulated and non-regulated emissions from all types of vessels and other port activities in order to enforce emission limits in waterfront cities

48346761TOPICSen

Programme: Cluster 5 Call 01-2026 (WP 2025)

This grant aims to support the development and demonstration of real-time monitoring solutions for regulated and non-regulated emissions from all types of vessels and other port activities. The core objective is to enable the enforcement of emission limits in waterfront cities, contributing to cleaner air and environmental protection. This is a SECTOR-SPECIFIC grant primarily targeting the maritime, transportation, and environmental technology sectors. The target recipients are organizations capable of developing and demonstrating innovative solutions in real operational environments, likely involving consortia of technology providers, port authorities, and research institutions. Geographically, the grant focuses on EU waterfront cities and TEN-T ports, requiring demonstration activities across at least six distinct ports located in diverse European sea basins. A key filtering criterion is the ability to conduct demonstrations in a real operational environment and to formally collaborate with the European Cities Mission Platform.

Funding

Up to 8000000.00 EUR

Deadline

Jan. 20, 2026, midnight

Details

Leveraging Network Infrastructure to Conduct Innovative Research for Women, Children, Pregnant and Lactating Women, and Persons with Disabilities (UG3/UH3 - Clinical Trial Optional)

PAR-25-311

Programme: National Institutes of Health (NIH)

The core objective of this grant is to leverage existing NICHD clinical research network infrastructure to conduct innovative, multisite, investigator-initiated clinical trials and observational studies. It specifically targets research relevant to infants, children, women (including pregnant and lactating), and persons with disabilities. This grant is SECTOR-SPECIFIC. - Target recipient type: Research institutions, universities, non-profits, for-profits, and government entities that can conduct clinical research. - Target size: Not specified, but organizations must have the capacity and infrastructure for multisite clinical research. - Geographic scope: Organizations must be US-based. Non-domestic components of US organizations are eligible. Research may involve international sites if affiliated with specific NICHD Networks (e.g., Global Network). - Key filtering criteria: Must propose to utilize a NICHD Network infrastructure; require approval of a concept proposal prior to full application; focus on clinical trials or observational studies; relate to the health of women, children, pregnant/lactating women, or persons with disabilities. - Grant frequency: Recurring, as it is a reissue of a previous funding opportunity (PAR-23-037).

Funding

Up to 6250000.00 USD

Deadline

Nov. 15, 2027, 5 p.m.

Details

InnoNext - Next Generation Innovation Talents' Initiative

10401COMPETITIVE_CALLen

Programme: Horizon Europe

The InnoNext initiative aims to promote knowledge exchange and collaboration between top European academic talents (researchers) and innovative start-ups/SMEs by offering fully funded innovation internships. - Core objective: Facilitate talent mobility and skill development by connecting researchers with companies for practical innovation projects. - Target recipient: Individual researchers (talents) from specific European research programs and European qualified start-ups/SMEs acting as hosting companies. - SECTOR-AGNOSTIC - Geographic scope: European countries, specifically involving researchers and companies within the European research ecosystem. - Key filtering criteria: Applicant's affiliation with specific EU research programs (ERC, EIC Pathfinder, EIT, MSCA, RI) for talents, and EIC/EIT affiliation for hosting companies. - Grant frequency: Open call, ongoing until July 2026, implying recurring opportunities within this period.

Funding

Up to 15900.00 EUR

Deadline

July 31, 2026, 11:59 p.m.

Details

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)

PAR-25-059

Programme: Innovation Grants to Nurture Initial Translational Efforts (IGNITE)

This grant, part of the 'Innovation Grants to Nurture Initial Translational Efforts (IGNITE)' suite, aims to accelerate the development of new treatments for neurological or neuromuscular disorders. It specifically funds early-stage translational research focused on developing in vitro, ex vivo, or in vivo assays and conducting iterative screening to identify and characterize potential therapeutic agents. This is a SECTOR-SPECIFIC grant, exclusively targeting the healthcare/biotechnology sector, specifically in neuroscience and drug discovery. Eligible applicants are diverse, ranging from academic institutions and non-profits to small and large for-profit organizations, and various government entities. Key filtering criteria for initial screening: Your project must focus on neurological or neuromuscular disorders, involve assay development and therapeutic agent identification through screening, and explicitly not propose clinical trials or late-stage therapeutic optimization. The geographic scope is US and international. The grant is offered through a recurring program with multiple application deadlines each year, indicating ongoing commitment to this research area.

Funding

Up to 750000.00 USD

Deadline

Oct. 20, 2027, 5 p.m.

Details

NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Clinical Trial Required)

PAR-24-211

Programme: National Institutes of Health (NIH) Research Career Development Program

The NHLBI Career Transition Award (K22) aims to support highly qualified postdoctoral fellows and doctoral-level researchers currently training within the NHLBI Division of Intramural Research. Its core objective is to facilitate their transition to independent junior investigator positions at extramural institutions. The grant provides a two-phase support model: a mentored intramural phase (up to two years) followed by an independent extramural phase (three years). Applicants must propose to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial. This is a SECTOR-SPECIFIC grant focused on biomedical, behavioral, and clinical research relevant to heart, lung, and blood diseases. The geographic scope is limited to the United States (including U.S. Territories and Possessions), as foreign organizations are not eligible to apply. This is a recurring grant opportunity, reissued from PAR-22-040, with multiple application deadlines each year until its expiration date.

Funding

Up to 747000.00 USD

Deadline

June 12, 2027, 5 p.m.

Details

Mechanistic links between diet, lipid metabolism, and tumor growth and progression (U01 Clinical Trial Not Allowed)

PAR-25-119

Programme: National Cancer Institute (NCI), National Institutes of Health (NIH)

This grant, PAR-25-119, from the National Cancer Institute (NCI) and National Institutes of Health (NIH), aims to fund fundamental mechanistic investigations into the connections between diet, lipid metabolism, and tumor growth and progression. The primary objective is to identify and define the molecular mechanisms through which lipids link diet with cancer biology, bridging the fields of nutrition and molecular metabolism, and stimulating research and tool development in this complex area. This is a SECTOR-SPECIFIC grant focused on cancer research, nutrition, and metabolism. The target recipients are diverse U.S.-based organizations, including higher education institutions, nonprofits, for-profit businesses, and various government entities. The grant does not allow clinical trials. It is a recurring funding opportunity, being a reissue of a previous announcement, with multiple application cycles per year. This opportunity is ideal for research teams looking to conduct basic science research in the intersection of diet, metabolism, and cancer.

Funding

Up to 500000.00 USD

Deadline

Oct. 23, 2025, 9 p.m.

Details

Akademia Dostępności - Wsparcie dla Firm

FERS.01.03

Programme: Fundusze Europejskie dla Rozwoju Społecznego 2021-2027

  • Core Objective: To enhance accessibility competencies among businesses and their employees, focusing on universal design principles and the commercialization of accessibility solutions.
  • Target Recipient Type and Size: Primarily targets existing micro, small, medium, and large enterprises, including social economy enterprises that engage in business activities.
  • Designation: SECTOR-AGNOSTIC
  • Geographic Scope: Nationwide in Poland ('CAŁY KRAJ').
  • Key Filtering Criteria: Businesses interested in improving accessibility and universal design within their operations, products, or services. Size of enterprise (micro, small, medium, large).
  • Grant Frequency and Program Context: This is a specific project called 'Akademia Dostępności' with a defined start and end date (2025-2027), funded under the European Funds for Social Development 2021-2027 program. It offers support services rather than direct financial grants to businesses.

Funding

Up to None PLN

Deadline

Dec. 31, 2027, midnight

Details

Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)

PAR-23-157

Programme: National Institute on Drug Abuse (NIDA) / National Institutes of Health (NIH)

This grant, PAR-23-157, aims to support exploratory and developmental clinical research focused on understanding the neurobiological mechanisms underlying Substance Use Disorders (SUD). It is primarily for researchers and institutions globally who can conduct high-risk, high-reward studies to advance scientific knowledge in this area. This grant is SECTOR-SPECIFIC, focusing on healthcare research related to substance use. The primary target recipients are research organizations of various types, from higher education institutions to non-profits and for-profit organizations, as well as government entities. The grant uses a phased innovation award mechanism (R61/R33), with an initial exploratory phase followed by a potential expansion phase.

Funding

Up to 500000.00 USD

Deadline

March 13, 2026, 10 p.m.

Details

Vrijstelling van vennootschapsbijdrage

VLAIO-198

Programme: VLAIO

This grant aims to provide a temporary exemption from the annual company contribution for newly established companies. It specifically targets personal partnerships (personenvennootschappen) in their early years of operation. - Core Objective: To grant a temporary exemption from the annual company contribution. - Target Recipient Type: Personal partnerships (personenvennootschappen). - Target Recipient Size: Not defined by employee count; contribution amount depends on balance sheet total. - SECTOR-AGNOSTIC - Geographic Scope: Flanders, Belgium. - Key Filtering Criteria: Legal form, company age, and prior self-employment history of partners. - Grant Frequency: Recurring annual exemption for the first three years of a company's existence.

Funding

Up to 2995.41 EUR

Deadline

Dec. 31, 2025, 10:59 p.m.

Details

Development of sustainable and design-to-cost batteries with (energy-)efficient manufacturing processes and based on advanced and safer materials (Batt4EU Partnership)

HORIZON-CL5-2026-01-D2-01

Programme: Horizon Europe

This grant aims to drive the development of next-generation, sustainable, and cost-effective batteries, focusing on efficient manufacturing processes and advanced, safer materials. The core objective is to improve the affordability of electric mobility and enhance the competitiveness of the European battery value chain, while reducing reliance on Critical Raw Materials (CRMs). It is designed to support the transformation towards a carbon-neutral society by enabling zero-emission mobility and renewable energy storage. This funding opportunity targets organizations involved in advanced battery research, development, and manufacturing, including industry players, research institutions, and universities. It is explicitly SECTOR-SPECIFIC, focusing on the battery technology and electric mobility sectors. The geographic scope primarily covers EU Member States and countries associated with Horizon Europe. Key filtering criteria for initial screening include a focus on specific battery chemistries (LMFP/HLM lithium-ion or sodium-ion), the ability to demonstrate cell prototypes at a pilot level, and a strong commitment to integrating Safe and Sustainable by Design principles throughout the project. This specific topic is part of the Horizon Europe Work Programme 2025, with calls generally occurring periodically within the overall program framework.

Funding

Up to 8000000.00 EUR

Deadline

Jan. 20, 2026, midnight

Details

NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)

PAR-25-090

Programme: National Institutes of Health (NIH) - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

This grant, PAR-25-090, is a planning cooperative agreement (U34) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) designed to support the initial administrative and preparatory phases of investigator-initiated, high-risk multi-center clinical studies. The primary objective is to facilitate the rigorous planning and documentation required before participant recruitment can begin for complex clinical studies, ultimately leading to a full-scale clinical study (U01). This grant is SECTOR-SPECIFIC, focusing exclusively on diseases within the mission of NIDDK (e.g., diabetes, digestive, and kidney diseases). It targets research institutions, non-profits, and for-profit organizations (including small businesses) based in the United States. Foreign organizations are not eligible to apply, but foreign components (e.g., for specific data analyses) of US-based organizations are allowed. Key filtering criteria: The proposed clinical study must be high-risk, as defined by NIDDK, and multi-center (more than one clinical research center). It's a planning grant, not for conducting preliminary data collection, pilot studies, or the clinical study itself. Consultation with NIDDK staff is strongly encouraged prior to application. This is a recurring grant opportunity, reissued from PAR-24-094, indicating an ongoing program context for supporting high-risk clinical study planning.

Funding

Up to 225000.00 USD

Deadline

June 10, 2027, 9 p.m.

Details

IDeA Clinical & Translational Research Network (CTR-N) Award (P50 - Clinical Trial Optional)

PAR-23-241

Programme: Institutional Development Award (IDeA) program

  • Core objective: To support and enhance biomedical research capacity, clinical and translational (C&T) research infrastructure, and workforce development within health organizations across specific IDeA-eligible states.
  • Target recipient: Health research organizations and associated community clinics within IDeA states.
  • Size: Organizations with established research administration infrastructure and a track record of externally funded C&T research grants.
  • Designation: SECTOR-SPECIFIC
  • Geographic scope: IDeA-eligible U.S. states and Puerto Rico, forming statewide or multi-state regional networks.
  • Key filtering criteria: Location in an IDeA state, existing C&T research grants, ability to form/lead a robust network, and focus on broad health challenges rather than narrow disease/population.
  • Grant frequency: Recurring (this is a reissue of a previous funding opportunity).

Funding

Up to 3300000.00 USD

Deadline

Oct. 9, 2025, 9 p.m.

Details

NEI Small Business Innovation Research (SBIR) Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U44-Clinical Trial Required)

PAR-24-066

Programme: Small Business Innovation Research (SBIR) Cooperative Agreements

This grant, the NEI Small Business Innovation Research (SBIR) Cooperative Agreement (U44), aims to support early-stage clinical trials with greater than minimal risk that evaluate interventions for vision disorders. - Single, clear statement of grant's core objective: To fund investigator-initiated clinical trials by small businesses focused on screening, diagnosing, preventing, or treating vision disorders, leading to commercialization. - Explicit identification of target recipient type and size: Small Business Concerns (SBCs) with not more than 500 employees. - MUST state if grant is 'SECTOR-SPECIFIC' or 'SECTOR-AGNOSTIC': SECTOR-SPECIFIC (Healthcare: Vision Research). - Geographic scope and any location requirements: United States-based organizations; all research and development activities must be performed within the United States and its territories. - Key filtering criteria for initial grant screening: Must be a US-based SBC, proposing an early-stage clinical trial (Phase I/II) for vision disorders that is greater than minimal risk, with a strong commercialization plan. - Grant frequency and program context: This is a recurring funding opportunity under the NIH SBIR program, offering multiple application deadlines annually. It uses the U44 cooperative agreement mechanism, designed for early-stage clinical trials with substantial NIH involvement, distinct from other NIH clinical trial mechanisms.

Funding

Up to 2000000.00 USD

Deadline

May 27, 2026, 10 p.m.

Details

992 results. Page 39 of 50.